Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Author(s): Ziba Aghsaeifard and Reza Alizadeh*

DOI: 10.2174/1871520623666230602143525

DownloadDownload PDF Flyer Cite As
Managing Cancer Treatment in Patients with Renal Dysfunction: The Role of Chemotherapy

Page: [1811 - 1818] Pages: 8

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Malignancy is characterized by damage to several vital organs, and utilizing chemotherapy as a treatment option can have toxic effects on healthy body tissues. Kidney function is commonly compromised by cancer and chemotherapy. These effects can be pre-renal, intrarenal, or postrenal. Tumor lysis syndrome and electrolyte disturbances are also common in this group of patients. Etiologies of this dysfunction are poorly understood; therefore, careful monitoring and management of renal function are required in such cases. This narrative review aimed to highlight some of the common renal abnormalities among patients receiving cancer and chemotherapy.

Keywords: Malignancy, kidney, chemotherapy, cancer, dysfunction, tumor.

[1]
Aghsaeifard, Z.; Ghafarzadeh, M.; Alizadeh, R. Pregnancy and sex hormone changes after kidney transplant. Clin. Invest. Ginecol. Obstet., 2023, 50(1), 100812.
[http://dx.doi.org/10.1016/j.gine.2022.100812]
[2]
Canet, E.; Zafrani, L.; Lambert, J.; Thieblemont, C.; Galicier, L.; Schnell, D.; Raffoux, E.; Lengline, E.; Chevret, S.; Darmon, M.; Azoulay, E. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One, 2013, 8(2), e55870.
[http://dx.doi.org/10.1371/journal.pone.0055870] [PMID: 23457485]
[3]
Alizadeh, R.; Aghsaeifard, Z. Two-way road of kidney and hypercalcemia: A narrative review. Cardiovasc. Hematol. Disord. Drug Targets, 2022, 22(4), 200-206.
[http://dx.doi.org/10.2174/1871529X23666221205143041] [PMID: 36475333]
[4]
Rosner, M.H.; Perazella, M.A. Acute kidney injury in patients with cancer. N. Engl. J. Med., 2017, 376(18), 1770-1781.https://www.nejm.org/doi/full/10.1056/NEJMra1613984
[http://dx.doi.org/10.1056/NEJMra1613984] [PMID: 28467867]
[5]
Aghsaeifard, Z.; Alizadeh, R.; Bagheri, N. Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch. Physiol. Biochem., 2022, 128(3), 703-707.
[http://dx.doi.org/10.1080/13813455.2020.1720742] [PMID: 31994917]
[6]
Miao, J.; Sise, M.E.; Herrmann, S.M. Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. Front. Neurol., 2022, 2, 1017921.
[http://dx.doi.org/10.3389/fneph.2022.1017921]
[7]
Alizadeh, R.; Aghsaeifard, Z. Clinical post-transplant lymphoproliferative disorders. Cardiovasc. Hematol. Disord. Drug Targets, 2022, 22(2), 96-103.
[http://dx.doi.org/10.2174/1871529X22666220804155810]
[8]
Santos, M.L.C.; Brito, B.B.; Silva, F.A.F.; Botelho, A.C.S.; Melo, F.F. Nephrotoxicity in cancer treatment: An overview. World J. Clin. Oncol., 2020, 11(4), 190-204.
[http://dx.doi.org/10.5306/wjco.v11.i4.190] [PMID: 32355641]
[9]
Małyszko, J.; Kozlowski, L.; Kozłowska, K.; Małyszko, M.; Małyszko, J. Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget, 2017, 8(39), 66601-66619.
[http://dx.doi.org/10.18632/oncotarget.18094] [PMID: 29029541]
[10]
Amarapurkar, P.; Bou-Slaiman, S.; Madrid, B.; Ladino, M. Paraneoplastic glomerular disease: The struggle is real. J. Onco-Nephrol., 2019, 3(1), 31-38.
[http://dx.doi.org/10.1177/2399369319828732]
[11]
Lefaucheur, C.; Stengel, B.; Nochy, D.; Martel, P.; Hill, G.S.; Jacquot, C.; Rossert, J. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int., 2006, 70(8), 1510-1517.
[http://dx.doi.org/10.1038/sj.ki.5001790] [PMID: 16941021]
[12]
Jhaveri, K.D.; Shah, H.H.; Calderon, K.; Campenot, E.S.; Radhakrishnan, J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int., 2013, 84(1), 34-44.
[http://dx.doi.org/10.1038/ki.2012.484] [PMID: 23364518]
[13]
Aghsaeifard, Z.; Alizadeh, R. Drug-induced interstitial nephritis as a result of sodium valproate and triamterene. Urol. Case Rep., 2020, 33, 101329.
[http://dx.doi.org/10.1016/j.eucr.2020.101329] [PMID: 33102031]
[14]
Beck, L.H., Jr PLA2R and THSD7A: Disparate paths to the same disease? J. Am. Soc. Nephrol., 2017, 28(9), 2579-2589.
[http://dx.doi.org/10.1681/ASN.2017020178] [PMID: 28674044]
[15]
Küppers, R.; Schwering, I.; Bräuninger, A.; Rajewsky, K.; Hansmann, M.L. Biology of Hodgkin’s lymphoma. Ann. Oncol., 2002, 13(Suppl. 1), 11-18.
[http://dx.doi.org/10.1093/annonc/13.S1.11] [PMID: 12078890]
[16]
Cambier, Jean-François; Ronco, Pierre Onco-nephrology: Glomerular diseases with cancer. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1701-1712.
[http://dx.doi.org/10.2215/CJN.03770412]
[17]
Ronco, P.; Plaisier, E. Immunoglobulin light (heavy)-chain deposition disease: From molecular medicine to pathophysiology-driven therapy. Clin. J. Amer. Soc. Nephrol., 2006, 1(6), 1342-1350.
[http://dx.doi.org/10.2215/CJN.01730506]
[18]
Gnemmi, V.; Leleu, X.; Provot, F.; Moulonguet, F.; Buob, D. Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia. Am. J. Kidney Dis., 2012, 60(3), 487-491.
[http://dx.doi.org/10.1053/j.ajkd.2012.01.030] [PMID: 22721930]
[19]
Toriu, N.; Sawa, N.; Imafuku, A.; Hasegawa, E.; Sekine, A.; Mizuno, H.; Yamanouchi, M.; Hiramatsu, R.; Hayami, N.; Hoshino, J.; Kawada, M.; Suwabe, T.; Ohashi, K.; Fujii, T.; Ubara, Y. Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. CEN Case Rep., 2020, 9(4), 347-353.
[http://dx.doi.org/10.1007/s13730-020-00485-7] [PMID: 32378178]
[20]
Heo, M.H.; Kim, H.K.; Lee, H.; Ahn, M.J. Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: A case report. J. Thorac. Oncol., 2017, 12(8), e103-e105.
[http://dx.doi.org/10.1016/j.jtho.2017.03.011] [PMID: 28342816]
[21]
Wu, S.; Dahut, W.L.; Gulley, J.L. The use of bisphosphonates in cancer patients. Acta Oncol., 2007, 46(5), 581-591.
[http://dx.doi.org/10.1080/02841860701233435] [PMID: 17562434]
[22]
Jia, N.; Cormack, F.C.; Xie, B.; Shiue, Z.; Najafian, B.; Gralow, J.R. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer, 2015, 15(1), 535.
[http://dx.doi.org/10.1186/s12885-015-1536-y] [PMID: 26197890]
[23]
Miller, P.D. The kidney and bisphosphonates. Bone, 2011, 49(1), 77-81.
[http://dx.doi.org/10.1016/j.bone.2010.12.024] [PMID: 21232648]
[24]
Oberic, L.; Buffet, M.; Schwarzinger, M.; Veyradier, A.; Clabault, K.; Malot, S.; Schleinitz, N.; Valla, D.; Galicier, L.; Bengrine-Lefèvre, L.; Gorin, N.C.; Coppo, P. Cancer awareness in atypical thrombotic microangiopathies. Oncologist, 2009, 14(8), 769-779.
[http://dx.doi.org/10.1634/theoncologist.2009-0067] [PMID: 19684072]
[25]
Mielczarek, Ł. Brodziak, A.; Sobczuk, P.; Kawecki, M.; Cudnoch-Jędrzejewska, A.; Czarnecka, A.M. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother. Pharmacol., 2021, 87(6), 723-742.
[http://dx.doi.org/10.1007/s00280-021-04260-y] [PMID: 33768301]
[26]
Al-Nouri, Z.L.; Reese, J.A.; Terrell, D.R.; Vesely, S.K.; George, J.N. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125(4), 616-618.
[http://dx.doi.org/10.1182/blood-2014-11-611335] [PMID: 25414441]
[27]
Lien, Y.H.H.; Lai, L.W. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat. Rev. Nephrol., 2011, 7(2), 85-95.
[http://dx.doi.org/10.1038/nrneph.2010.171] [PMID: 21151207]
[28]
Hausberg, M.; Felten, H.; Pfeffer, S. Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer. Case Rep. Oncol., 2019, 12(1), 1-6.
[http://dx.doi.org/10.1159/000495031] [PMID: 30792638]
[29]
Kapiteijn, E.; Brand, A.; Kroep, J.; Gelderblom, H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol., 2007, 18(10), 1745-1747.
[http://dx.doi.org/10.1093/annonc/mdm454] [PMID: 17890216]
[30]
Morton, J.M.; George, J.N. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J. Oncol. Pract., 2016, 12(6), 523-530.https://ascopubs.org/doi/full/10.1200/jop.2016.012096
[http://dx.doi.org/10.1200/JOP.2016.012096] [PMID: 27288467]
[31]
Winters, J.L. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology (Am. Soc. Hematol. Educ. Program), 2017, 2017(1), 632-638.
[http://dx.doi.org/10.1182/asheducation-2017.1.632] [PMID: 29222314]
[32]
Lam, A.Q.; Humphreys, B.D. Onco-Nephrology. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1692-1700.
[http://dx.doi.org/10.2215/CJN.03140312] [PMID: 22879433]
[33]
Campbell, G.A.; Hu, D.; Okusa, M.D. Acute kidney injury in the cancer patient. Adv. Chronic Kidney Dis., 2014, 21(1), 64-71.
[http://dx.doi.org/10.1053/j.ackd.2013.08.002] [PMID: 24359988]
[34]
Okada, H.; Kikuta, T.; Kobayashi, T.; Inoue, T.; Kanno, Y. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Amer. Soc. Nephrol., 2005, 16(1), 133-143.
[http://dx.doi.org/10.1681/ASN.2004040339]
[35]
Aghsaeifard, Z.; Latifi, M.; Bagherpour, F.; Rahbar, M.; Rahimzadeh, H.; Namdari, F.; Dialameh, H.; Taheri Mahmoudi, M.; Dehghani, S. Choriocarcinoma transmitted with the transplant: Case study. SAGE Open Med. Case Rep., 2022, 10, 2050313X2210875.
[http://dx.doi.org/10.1177/2050313X221087567] [PMID: 35449531]
[36]
Vaglio, A.; Maritati, F. Idiopathic retroperitoneal fibrosis. J. Am. Soc. Nephrol., 2016, 27(7), 1880-1889.
[http://dx.doi.org/10.1681/ASN.2015101110] [PMID: 26860343]
[37]
Surcel, C.; Mirvald, C.; Pavelescu, C.; Gingu, C.; Carmen, S.; Emre, H.; Ioanel, S. Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective. Ther. Adv. Urol., 2015, 7(2), 85-99.
[http://dx.doi.org/10.1177/1756287214565637]
[38]
Ingles Garces, A.H.; Ang, J.E.; Ameratunga, M.; Chénard-Poirier, M.; Dolling, D.; Diamantis, N.; Seeramreddi, S.; Sundar, R.; de Bono, J.; Lopez, J.; Banerji, U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Eur. J. Cancer, 2018, 104(104), 32-38.
[http://dx.doi.org/10.1016/j.ejca.2018.08.019] [PMID: 30316017]
[39]
Gupta, R.; Matthew, N.J. Hypercalcemia due to vitamin D-secreting hodgkin’s lymphoma exacerbated by oral calcium supplementation. Endocrine Practice, 12(2), 227-229.
[http://dx.doi.org/10.4158/EP.12.2.227]
[40]
Berardi, R.; Rinaldi, S.; Caramanti, M.; Grohè, C.; Santoni, M.; Morgese, F.; Torniai, M.; Savini, A.; Fiordoliva, I.; Cascinu, S. Hyponatremia in cancer patients: Time for a new approach. Crit. Rev. Oncol. Hematol., 2016, 102, 15-25.
[http://dx.doi.org/10.1016/j.critrevonc.2016.03.010] [PMID: 27066939]
[41]
Onitilo, A.A.; Kio, E.; Doi, S.A.R. Tumor-related hyponatremia. Clin. Med. Res., 2007, 5(4), 228-237.
[http://dx.doi.org/10.3121/cmr.2007.762] [PMID: 18086907]
[42]
Mentrasti, G.; Scortichini, L.; Torniai, M.; Giampieri, R.; Morgese, F.; Rinaldi, S.; Berardi, R. Syndrome of inappropriate antidiuretic hormone secretion (SIADH): Optimal management. Ther. Clin. Risk Manag., 2020, 16, 663-672.
[http://dx.doi.org/10.2147/TCRM.S206066] [PMID: 32801723]
[43]
Verzicco, I.; Regolisti, G.; Quaini, F.; Bocchi, P.; Brusasco, I.; Ferrari, M.; Passeri, G.; Cannone, V.; Coghi, P.; Fiaccadori, E.; Vignali, A.; Volpi, R.; Cabassi, A. Electrolyte disorders induced by antineoplastic drugs. Front. Oncol., 2020, 10, 779.
[http://dx.doi.org/10.3389/fonc.2020.00779] [PMID: 32509580]
[44]
Shirali, A. Electrolyte and acid-base disorders in malignancy.Onco-nephrology curriculum; American society of nephrology: Washington, DC, USA, 2016.
[45]
Rosner, M.H.; Perazella, M.A. Acute kidney injury in the patient with cancer. Kidney Res. Clin. Pract., 2019, 38(3), 295-308.
[http://dx.doi.org/10.23876/j.krcp.19.042] [PMID: 31284363]
[46]
Bowman, B.T. Electrolyte disorders associated with cancer. Journal of Onco-Nephrology, 2017, 1(1), 30-35.
[http://dx.doi.org/10.5301/jo-n.5000004]
[47]
Chaudhary, D.P.; Sharma, R.; Bansal, D.D. Implications of magnesium deficiency in type 2 diabetes: a review. Biol. Trace Elem. Res., 2010, 134(2), 119-129.
[http://dx.doi.org/10.1007/s12011-009-8465-z] [PMID: 19629403]
[48]
Lam, M.; Adelstein, D.J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am. J. Kidney Dis., 1986, 8(3), 164-169.
[http://dx.doi.org/10.1016/S0272-6386(86)80020-8] [PMID: 3752072]
[49]
Rude, R.K. Magnesium deficiency: a cause of heterogeneous disease in humans. J. Bone Miner. Res., 1998, 13(4), 749-758.
[http://dx.doi.org/10.1359/jbmr.1998.13.4.749] [PMID: 9556074]
[50]
Dreizen, S.; McCredie, K.B.; Keating, M.J.; Andersson, B.S. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad. Med., 1990, 87(1), 163-170, 170.
[http://dx.doi.org/10.1080/00325481.1990.11704531] [PMID: 2296564]
[51]
Gupta, D.; Vashi, P.G.; Trukova, K.; Lis, C.G.; Lammersfeld, C.A. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp. Ther. Med., 2011, 2(2), 181-193.
[http://dx.doi.org/10.3892/etm.2011.205] [PMID: 22977487]
[52]
Pullar, J.; Carr, A.; Vissers, M. The roles of vitamin C in skin health. Nutrients, 2017, 9(8), 866.
[http://dx.doi.org/10.3390/nu9080866] [PMID: 28805671]
[53]
Darmon, M.; Vincent, F.; Camous, L.; Canet, E.; Bonmati, C.; Braun, T.; Caillot, D.; Cornillon, J.; Dimicoli, S.; Etienne, A.; Galicier, L.; Garnier, A.; Girault, S.; Hunault-Berger, M.; Marolleau, J.P.; Moreau, P.; Raffoux, E.; Recher, C.; Thiebaud, A.; Thieblemont, C.; Azoulay, E. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br. J. Haematol., 2013, 162(4), 489-497.
[http://dx.doi.org/10.1111/bjh.12415] [PMID: 23772757]
[54]
Sherwood, G.B.; Paschal, R.D.; Adamski, J. Rasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. Clin. Case Rep., 2016, 4(4), 315-319.
[http://dx.doi.org/10.1002/ccr3.495] [PMID: 27099716]
[55]
Mirrakhimov, A.E.; Ali, A.M.; Khan, M.; Barbaryan, A. Tumor lysis syndrome in solid tumors: An up to date review of the literature. Rare Tumors, 2014, 6(2), 68-76.
[http://dx.doi.org/10.4081/rt.2014.5389] [PMID: 25002953]
[56]
Abu-Alfa, A.K.; Younes, A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am. J. Kidney Dis., 2010, 55(5)(Suppl. 3), S1-S13.
[http://dx.doi.org/10.1053/j.ajkd.2009.10.056] [PMID: 20420966]
[57]
Reed, D.R.; Pierce, E.J.; Sen, J.M.; Keng, M.K. A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. Cancer Manag. Res., 2019, 11, 8065-8072.
[http://dx.doi.org/10.2147/CMAR.S190084] [PMID: 31507329]
[58]
Chen, C.; Lü, J.M.; Yao, Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: An overview. Med. Sci. Monit., 2016, 22, 2501-2512.
[http://dx.doi.org/10.12659/MSM.899852] [PMID: 27423335]
[59]
Pession, A.; Melchionda, F.; Castellini, C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics, 2008, 2(1), 129-141.
[PMID: 19707436]
[60]
Chao, J.; Terkeltaub, R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep., 2009, 11(2), 135-140.
[http://dx.doi.org/10.1007/s11926-009-0019-z] [PMID: 19296886]
[61]
Bessmertny, O.; Robitaille, L.; Cairo, M. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr. Pharm. Des., 2005, 11(32), 4177-4185.
[http://dx.doi.org/10.2174/138161205774913291] [PMID: 16375739]
[62]
Cairo, M.S.; Bishop, M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol., 2004, 127(1), 3-11.
[http://dx.doi.org/10.1111/j.1365-2141.2004.05094.x] [PMID: 15384972]
[63]
Vadhan-Raj, S.; Fayad, L.E.; Fanale, M.A.; Pro, B.; Rodriguez, A.; Hagemeister, F.B.; Bueso-Ramos, C.E.; Zhou, X.; McLaughlin, P.W.; Fowler, N.; Shah, J.; Orlowski, R.Z.; Samaniego, F.; Wang, M.; Cortes, J.E.; Younes, A.; Kwak, L.W.; Sarlis, N.J.; Romaguera, J.E. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann. Oncol., 2012, 23(6), 1640-1645.
[http://dx.doi.org/10.1093/annonc/mdr490] [PMID: 22015451]
[64]
Nakamura, M.; Oda, S.; Sadahiro, T.; Hirayama, Y.; Tateishi, Y.; Abe, R.; Hirasawa, H. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus. Apheresis Sci., 2009, 40(1), 41-47.
[http://dx.doi.org/10.1016/j.transci.2008.11.004] [PMID: 19109071]
[65]
Lin, C.J.; Chen, H.H.; Hsieh, R.K.; Chen, Y.C.; Wu, C.J. Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. Med. Oncol., 2009, 26(1), 93-95.
[http://dx.doi.org/10.1007/s12032-008-9064-0] [PMID: 18770053]
[66]
Humphreys; Benjamin, D. Soiffer, R.J.; Magee, C.C. Renal failure associated with cancer and its treatment: An update. J. Amer. Soc. Nephrol., 2005, 16(1), 151-161.
[http://dx.doi.org/10.1681/ASN.2004100843]
[67]
Wilson, F.P.; Berns, J.S. Tumor lysis syndrome: new challenges and recent advances. Adv. Chronic Kidney Dis., 2014, 21(1), 18-26.
[http://dx.doi.org/10.1053/j.ackd.2013.07.001] [PMID: 24359983]
[68]
Małyszko, J.; Kozłowska, K.; Kozłowski, L.; Małyszko, J. Nephrotoxicity of anticancer treatment. Nephrol. Dial. Transplant., 2016, 32(6), gfw338.
[http://dx.doi.org/10.1093/ndt/gfw338] [PMID: 28339935]
[69]
Jagieła, J.; Bartnicki, P.; Rysz, J. Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int. J. Mol. Sci., 2021, 22(9), 4618.
[http://dx.doi.org/10.3390/ijms22094618] [PMID: 33924827]
[70]
Gupta, S.; Gudsoorkar, P.; Jhaveri, K.D. Acute kidney injury in critically Ill patients with cancer. Clin. J. Am. Soc. Nephrol., 2022, 17(9), 1385-1398.
[http://dx.doi.org/10.2215/CJN.15681221]
[71]
Chiruvella, V.; Annamaraju, P.; Guddati, A.K. Management of nephrotoxicity of chemotherapy and targeted agents. Am. J. Cancer Res., 2020, 10(12), 4151-4164.
[PMID: 33414992]
[72]
Lotfi, R.; Tehrani, F.R.; Dovom, M.R.; Torkestani, F.; Abedini, M.; Sajedinejad, S. Development of strategies to reduce cesarean delivery rates in iran 2012-2014: a mixed methods study. Int. J. Prev. Med., 2014, 5(12), 1552-1566.
[PMID: 25709791]
[73]
Li, H.; Xu, J.; Bai, Y.; Zhang, S.; Cheng, M.; Jin, J. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: A systematic review and meta-analysis. Invest. New Drugs, 2021, 39(3), 860-870.
[http://dx.doi.org/10.1007/s10637-020-01039-5] [PMID: 33409896]